Maryam Tehranipour | Pharmacology | Best Researcher Award

Published on by Health Scientists

Assoc. Prof. Dr. Maryam Tehranipour | Pharmacology | Best Researcher Award

Animal Physiology | Islamic Azad University | Iran

Dr. Maryam Tehranipour is an accomplished Associate Professor in the Department of Biology at the Islamic Azad University, Mashhad, Iran, recognized for her distinguished contributions to the fields of diabetes, metabolic disorders, neurobiology, oxidative stress, and cancer biology. Holding a Ph.D. in Animal Physiology, she has built a dynamic academic and research career integrating cellular physiology, pharmacology, and molecular mechanisms of disease. Her extensive publication record spans a broad spectrum of biomedical investigations, including neuroprotective strategies, natural product pharmacology, nanomedicine, and experimental models of diabetes and neurodegeneration. Dr. Tehranipour’s pioneering studies have elucidated the roles of oxidative damage, angiogenesis, and neuronal regeneration in disease progression and therapeutic recovery, particularly highlighting the potential of bioactive compounds and nanocarrier systems in drug design and targeted therapy. Her collaborative work has advanced understanding of diabetic complications, nerve injury repair, and cancer cell modulation through natural and synthetic agents. Beyond her prolific research output, she has played a significant role in mentoring undergraduate, graduate, and doctoral students, fostering scientific rigor and innovation in physiological research. Her scholarly influence is reflected through her indexed publications, contributions to interdisciplinary research networks, and global collaborations that link physiology, biochemistry, and nanotechnology for translational health impact. Dr. Tehranipour’s scientific endeavors emphasize the integration of experimental biology with clinical relevance, aiming to bridge laboratory discoveries with therapeutic applications. Through her ongoing research, she continues to contribute meaningfully to global biomedical science, particularly in developing sustainable and biologically safe therapeutic interventions addressing chronic and degenerative diseases that pose major public health challenges. She has 238 citations from 53 documents with an h-index of 9.

Profile: Scopus 

Featured Publications

1. The Umbelliprenin-CTAB cellulose nanocrystal delivery system prevents hyperglycemia in diabetic rats by activating the insulin receptor IR/PDK1 pathway. (2025). Scientific Reports. Open access.

2. The effects of N-butanol and ethyl acetate fractions of Ferula asafoetida hydroalcoholic extract on the expression of VEGF and FGF genes in the chorioallantoic membrane of chick embryos. (2025). Journal of Veterinary Research.Open access.

3. Bimetallic-based colorimetric aptasensor for the quantitative analysis of ampicillin using catalytic activity of ZrFe metal–organic framework and terminal deoxynucleotidyl transferase-assisted signal amplification. (2025). Bionanoscience. Open access.

4. The effect of Ziziphora clinopodioides hydroalcoholic extract on the neuronal density and histopathology of the hippocampal area CA2 in streptozotocin-induced Alzheimer’s model in male rats. (2025). Journal of Chemical Health Risks. Open access.

5. A novel alpha-terpineol-loaded niosome formulation coated with hyaluronic acid and evaluation of its anticancer properties in vitro. (2025). Journal of Molecular Liquids. Open access.

Reham Abdelkader | Pharmacology | Best Researcher Award

Published on by Health Scientists

Prof. Reham Abdelkader | Pharmacology | Best Researcher Award 

Head of department | German university in Cairo | Egypt

Dr. Reham Mahmoud Abdel-Kader, Professor of Pharmacology and Toxicology and Chair of the Department at the German University in Cairo, is a distinguished biomedical scientist whose research bridges molecular pharmacology, neurodegenerative diseases, and cancer biology with translational therapeutic innovation. Her scientific contributions focus on elucidating mitochondrial dysfunction, neuroinflammation, and cellular bioenergetics as critical mechanisms in Alzheimer’s disease and oncological disorders, advancing targeted treatment approaches through nanotechnology and pharmacogenomic insights. Dr. Abdel-Kader has established two active research groups investigating Alzheimer’s pathology and mitochondrial roles in breast cancer progression, fostering a strong translational link between bench discovery and therapeutic development. She has published widely in internationally recognized journals in pharmacology, neurobiology, and molecular medicine, and her work has received global recognition through prestigious conference presentations and features in leading scientific outlets. Her research has attracted significant international funding from agencies such as the Swiss National Science Foundation, DAAD-BMBF, and the Science and Technology Development Fund, reflecting the impact and sustainability of her scientific endeavors. A committed academic leader, she has played a vital role in curriculum development, accreditation processes, and capacity-building initiatives that enhance educational quality and research excellence within her institution. Dr. Abdel-Kader actively collaborates with leading scientists and institutions across Europe, including partnerships in Germany and Switzerland, fostering international scientific exchange and innovation. Her patent in nanocomposite synthesis further underscores her commitment to bridging pharmaceutical research and technology-based solutions. Through her scholarly rigor, mentorship, and collaborative leadership, Dr. Abdel-Kader continues to contribute significantly to global pharmacological sciences and to shaping the next generation of health researchers dedicated to advancing human health and societal well-being.

Profiles: Google Scholar | ORCID

Featured Publications

1. Leuner, K., Hauptmann, S., Abdel-Kader, R., Scherping, I., Keil, U., & others. (2007). Mitochondrial dysfunction: The first domino in brain aging and Alzheimer’s disease? Antioxidants & Redox Signaling,

2. Abdel-Kader, R., Hauptmann, S., Keil, U., Scherping, I., Leuner, K., Eckert, A., & others. (2007). Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacological Research,

3. Eckert, G. P., Renner, K., Eckert, S. H., Eckmann, J., Hagl, S., Abdel-Kader, R. M., & others. (2012). Mitochondrial dysfunction—A pharmacological target in Alzheimer’s disease. Molecular Neurobiology,

4. Franke, C., Nöldner, M., Abdel-Kader, R., Johnson-Anuna, L. N., Wood, W. G., & others. (2007). Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiology of Disease

5. Eckert, G. P., Schiborr, C., Hagl, S., Abdel-Kader, R., Müller, W. E., & Rimbach, G. (2013). Curcumin prevents mitochondrial dysfunction in the brain of the senescence-accelerated mouse-prone 8. Neurochemistry International.